Seed Innovations Limited Investee Company Update: Little Green Pharma Ltd
31 Março 2022 - 7:16AM
RNS Non-Regulatory
TIDMSEED
Seed Innovations Limited
31 March 2022
Seed Innovations Ltd / AIM: SEED / Sector: Closed End
Investments
31 March 2022
SEED Innovations Limited ("SEED" or the "Company")
Investee Company Update: Little Green Pharma Ltd
SEED Innovations Ltd, the AIM quoted company investing in fast
growing and industry leading businesses with a focus on the medical
cannabis, health and wellness space, is pleased to note an
announcement released by Telaleaf Health Inc. ('Telaleaf'), a
telemedicine company, who are entering into a joint sponsorship of
a second certificate course in medical cannabis for healthcare
professionals in Germany with portfolio company, Little Green
Pharma Ltd ('LGP').
SEED owns a holding of 7,324,796 ordinary shares in LGP
representing 3.1% of LGP's issued share capital.
The following extract from the announcement is set out without
material changes or adjustments and the announcement in full can be
accessed from the link below this section.
"Telaleaf and Little Green Pharma Sponsor Second Session of
Certificate Course in Medical Cannabis for Doctors in Germany
Berlin, Germany, March 28, 2022 --(PR.com)-- Telaleaf Health
Inc. ("Telaleaf" or the "Company"), a telemedicine company
transforming the delivery of cannabis care to patients, is pleased
to announce its joint sponsorship together with leading global
medical cannabis company Little Green Pharma Ltd. (or "LGP"), of
the second certificate course for doctors, pharmacists and relevant
professionals interested in the therapeutic application of cannabis
medicines.
The course titled, "The A-Z of cannabis-based therapy: Basics
and practical use of cannabis-based drugs in medical practice and
pharmacy" is hosted by Dresden International University and kicked
off its inaugural session September 30, 2021. The course is
developed and instructed by world-renown medical cannabis experts
Dr. Franjo Grotenhermen, Dr. Kirsten Müller-Vahl and Dr. Dennis
Stracke - delivering 82 lessons over a 12-week period. The second
session of this leading-edge course began March 24, 2022.
The course is a comprehensive, practice-oriented and
interdisciplinary certificate course for doctors, providing
in-depth knowledge of all aspects of cannabis-based therapy, which
doctors and pharmacists require for appropriate and responsible
therapeutic use of all cannabis-based drugs currently available for
prescription. Upon completion of the course, advanced training
points are awarded by the Saxon State Medical Association for those
who have the appropriate professional affiliation.
The many years of individual and combined clinical, practical
and scientific experience of the lecturers is of immense value to
the course participants, as well as their excellent knowledge of
emerging cannabis laws and the current political and legal
landscape in Germany, Europe and beyond.
"As a response to the popular demand by doctors for
participation in this course, we are pleased to announce that there
will be 2 more courses this year. The next course is scheduled to
start in the fall 2022 and the course after next is scheduled to
start in December 2022," said Eva Allouche, Telaleaf co-Founder and
Chief Operating Officer.
For more information and to register for the next courses, go
to: telaleaf.com/doctors.
About Telaleaf
Telaleaf is a telemedicine company transforming the delivery of
cannabis care by connecting patients to expert doctors, trained in
cannabis-based medicine, who conduct virtual medical visits and
provide personalized treatment plans. Our aim is to improve patient
outcomes, by improving the patient experience with high quality
treatment, ease of access and expert-led training to doctors, for
the most advanced virtual care in cannabis medicine.
About Little Green Pharma
Little Green Pharma is a leading global medicinal cannabis
business with key production assets in Australia and Europe. Our
goal is to improve patient access to GMP-grade cannabis medicines
around the world and transform lives for the better. To achieve
this, we prioritize assisting doctors with ongoing education on
treatment benefits and with the prescribing process to make it as
simple as possible.
- Ends -
For further information on the Company please visit www.seedinnovations.co or contact:
Ed McDermott SEED Innovations Email: info@seedinnovations.co
/ Ltd
Lance de Jersey
James Biddle Beaumont Cornish Tel: +44 (0) 207 628 3396
/Roland Cornish Limited,
Nomad
------------------- -----------------------------------
Isabella Pierre Shard Capital Tel: +44 (0)20 7186 9927
/Damon Heath Partners LLP
------------------- -----------------------------------
Catherine Leftley St Brides Partners Email: seed@stbridespartners.co.uk
/Isabelle Morris Ltd,
Financial PR
------------------- -----------------------------------
Notes
SEED Innovations is an AIM quoted investment company focused
primarily on disruptive high growth life sciences and technology
businesses particularly within the medical cannabis arena. The
Company's strategy is to identify early-stage opportunities that
have an upcoming investment catalyst and grow its portfolio in
terms of value whilst limiting the number of investee companies to
a level where relevant time can be devoted to each.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAWPUPGWUPPGUG
(END) Dow Jones Newswires
March 31, 2022 06:16 ET (10:16 GMT)
Fastforward Innovations (LSE:FFWD)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Fastforward Innovations (LSE:FFWD)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
